Results 151 to 160 of about 29,549 (204)

Tropomyosin 3 Gene Fusions in Cancers: From Mechanisms to Treatments-A Comprehensive Review. [PDF]

Cancer Med
Chen A, Li S, Guo C, Gu C, Gui J, Deng Y, Feng X, Mi Y.   +7 more
europepmc   +1 more source

ROS1 Gene Rearrangement Negative [PDF]

, 2020
openaire   +1 more source

Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions. [PDF]

Cancers (Basel)
Winter M, Jeroch J, Wetz M, Rauschendorf MA, Wild PJ.   +4 more
europepmc   +1 more source

Parallel submanifolds of complex projective space and their normal holonomy [PDF]

, 2009
Console, S., Di Scala, Antonio Jose'
core  

GOPC/ROS1 Fusion Protein [PDF]

, 2020
openaire   +1 more source

<i>ROS1</i> mutations promote an immunosuppressive tumor microenvironment via <i>MYC</i> to confer immune evasion in head and neck cancer. [PDF]

Cancer Drug Resist
Fang C, Zhang Q, Fang R, Li Y, Bai J, Huang X, Lu J, Chen D, Zhang Y, Chen Z.   +9 more
europepmc   +1 more source

Can radiomics in brain magnetic resonance imaging predict the mutational status of primary lung cancer based on brain metastasis? [PDF]

Pol J Radiol
Kuzan BN, Ilgın C, Geçmen GG, Işık N, Günbey HP, Emeç M.   +5 more
europepmc   +1 more source

GOPC/ROS1 Fusion Gene [PDF]

, 2020
openaire   +1 more source

Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial. [PDF]

JTO Clin Res Rep
Landi L, Chiari R, Tiseo M, Metro G, de Marinis F, Delmonte A, Novello S, Cortinovis DL, Galetta D, Bonanno L, Gridelli C, Morabito A, Grossi F, Torchia A, Giannarelli D, Borra G, Mazzoni F, Pilotto S, Cappuzzo F.   +18 more
europepmc   +1 more source

Taletrectinib in ROS1-positive NSCLC: bridging clinical trials and real-world practice. [PDF]

Ann Med Surg (Lond)
Zahra FT, Naveed F, Fatima M.
europepmc   +1 more source